Guardant Health (GH) Now Has A Harder Patent Fight After 23 Claims Survived

• Guardant Health (NasdaqGS:GH) faces higher legal pressure after the USPTO confirmed patentability of TwinStrand’s Duplex Sequencing patent claims.

• The US patent office upheld all 23 claims in TwinStrand Biosciences’ core Duplex Sequencing patent in a now unappealable ruling.

• This confirmation supports TwinStrand’s ongoing lawsuit that accuses Guardant Health of willful infringement related to its cancer testing technology.

• The USPTO decision on TwinStrand’s Duplex Sequencing patent should not be the only factor shaping your view on Guardant Health. Take a look at 2 warning signs (1 major) we have identified for Guardant Health.

Broader interest in DNA sequencing and molecular diagnostics is pushing fresh ideas onto the market, and it is worth scanning beyond the headline players through our screener containing 19 high quality undiscovered gems.

Guardant Health runs blood and tissue based tests for cancer detection and monitoring, so core intellectual property around DNA sequencing methods can influence how it competes with other molecular diagnostics providers. As a US based precision oncology specialist with a reported market cap of $20.7b, its commercial model relies heavily on protected technology and data assets.

Does the team leading Guardant Health have what it takes? See our full breakdown of the management team’s track record and compensation.

Patent ruling turns Guardant Health’s legal overhang into a leadership test

Guardant Health’s investment story asks whether a fast scaling cancer testing platform can absorb heavy legal obligations and still reach sustainable cash generation. This USPTO decision tightens the legal screws, so the Narrative now leans harder on how directors and executives handle royalties, product design choices, and cash burn.

A key factor is whether Guardant Health can translate current test volume trends, changes in Shield cost per test, and developments in reimbursement into sustainable cash generation while managing the impact of patent royalties and ongoing investment…

See how the full story points towards a $202 fair value for Guardant Health.

This ruling directly reinforces the risk catalyst around patent damages and royalties, and puts more weight on the board refresh that added Kevin Sayer and a new chief accounting officer. Leadership now has to integrate Duplex Sequencing liabilities into long term Shield and Guardant360 planning, while peers like Exact Sciences and Natera focus on product uptake rather than courtroom fallout.

The decision also pressures the cash burn constraint in the Narrative, since any future licensing costs or product changes sit on top of current losses of US$124.36 million in Q3 and US$356.58 million for the first nine months of 2026. Analysts have already flagged negative equity and continuing free cash flow outflows, so leadership discipline on spending and capital structure becomes a bigger part of how investors judge the Guardant Health story.

Updates like this show why you need a clear view of where Guardant Health is heading, because a consistent Narrative is what lets you weigh each legal or leadership twist in context rather than in isolation.

Guardant Health’s forecasts point to a very different destination than today’s headlines

Short term stories grab attention, but the projections for where Guardant Health could be a few years out tell a far more consequential story that today’s legal and cash flow debate barely touches. See where analysts expect Guardant Health to be in a few years.

This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]